ProCE Banner Activity

Meet Zanubrutinib, the Newest Bruton’s Tyrosine Kinase Inhibitor for Mantle Cell Lymphoma

Clinical Thought
Are you ready to include BTK inhibitor zanubrutinib as a treatment option for patients with MCL in your practice?

Released: March 24, 2020

Expiration: March 23, 2021

No longer available for credit.

Share

Faculty

John Pagel

John Pagel, MD, PhD

Associate Professor
Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene, Ltd.

Loxo Oncology subsidiary of Eli Lilly

Faculty Disclosure

Primary Author

John Pagel, MD, PhD

Associate Professor
Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

John Pagel, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Gilead Sciences, and Pharmacyclics.